SABA Study

Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators

Status: Completed in 2013

Battery Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators was released online in October 2013 by EP EuroPace and is the first independent, head-to-head, retrospective study comparing battery longevity of contemporary cardiac resynchronization therapy defibrillators (CRT-Ds).

This retrospective, observational study found that "the 4-year survival rate of device battery was significantly worse for Medtronic devices compared with devices from other manufacturers (94% for Boston Scientific, 67% for Medtronic, and 92% for St Jude Medical, P <0.001)."


  • During the 2.7 ± 1.5 years follow-up, 25% of Medtronic devices reached ERI compared to 4% for Boston Scientific devices and 7% for St. Jude Medical devices1
  • The 4-year survival rate2 of device battery was 94% for Boston Scientific's devices, compared to 67% for Medtronic's devices and 92% for St. Jude Medical's devices1
  • Boston Scientific had fewer devices (both in terms of number of devices and percent of devices) reach ERI than Medtronic or St. Jude Medical1,2

Boston Scientific offers CRT-Ds designed to be the world’s longest lasting – with nearly double the battery capacity of other available CRT-D models.